Tech Center 1600 • Art Units: 1617 1622 1623 1627
This examiner grants 30% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17198023 | METHODS OF TREATING RHEUMATOID ARTHRITIS AND FOR PREDICTING THE RESPONSE TO METHOTREXATE | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18105030 | BETA-HYDROXYBUTYRIC ACID COMPOSITIONS AND METHODS FOR ORAL DELIVERY OF KETONE BODIES | Final Rejection | AXCESS GLOBAL SCIENCES, LLC |
| 19315081 | THYMOL AND CITRIC ACID DISINFECTANT WITH IMPROVED EFFICIENCY | Final Rejection | ROCKDALE RESEARCH AND IP HOLDINGS, LLC |
| 18411245 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | Final Rejection | CHEMOCENTRYX, INC. |
| 19253088 | BIPHENYL SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF KIDNEY DISEASES OR DISORDERS | Non-Final OA | Travere Therapeutics, Inc. |
| 19253120 | BIPHENYL SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF KIDNEY DISEASES OR DISORDERS | Final Rejection | Travere Therapeutics, Inc. |
| 17274950 | ALKYNYL NICOTINAMIDE COMPOUNDS AS KINASE INHIBITORS | Final Rejection | PURDUE RESEARCH FOUNDATION |
| 17332431 | COMPOSITIONS AND METHODS FOR DELIVERING THERAPEUTIC AGENTS INTO THE COLON | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 17766728 | External Preparation for Treating Epilepsy or Autism Spectrum Disorder | Final Rejection | OSAKA UNIVERSITY |
| 18826821 | TOBACCO HARM REDUCTION AND PAIN RELIEF PRODUCTS AND METHODS THEREOF | Final Rejection | Ready Mix Naturals, LLC |
| 17513383 | PHARMACEUTICAL AGENT FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS OR SUPPRESSING DISEASE PROGRESS THEREOF | Final Rejection | Mitsubishi Tanabe Pharma Corporation |
| 17885498 | METHODS OF TREATING MIXED DYSLIPIDEMIA AND HYPERTRIGLYCERIDEMIA | Final Rejection | Kowa Company, Ltd. |
| 18429719 | ALDOSE REDUCTASE INHIBITORS FOR TREATING SORBITOL DEHYDROGENASE DEFICIENCY | Non-Final OA | APPLIED THERAPEUTICS, INC. |
| 17715401 | ALDOSE REDUCTASE INHIBITORS FOR TREATMENT OF PHOSPHOMANNOMUTASE 2 DEFICIENCY | Final Rejection | Applied Therapeutics, Inc. |
| 18022982 | PHARMACEUTICAL COMPOSITION OF SINGLE DOSAGE FORM FOR TREATING OR PREVENTING HYPERTENSION AND HYPERLIPIDEMIA | Final Rejection | Daewoong Pharmaceutical Co., Ltd. |
| 17603886 | QUINOLINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING EWING'S SARCOMA | Non-Final OA | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. |
| 18284941 | THERAPEUTIC AGENT FOR GAIT DISTURBANCE | Non-Final OA | NIPPON SHINYAKU CO., LTD. |
| 18257325 | USE OF NK1 ANTAGONIST PRODRUG COMPOUND IN COMBINATION WITH 5-HT3 RECEPTOR ANTAGONIST | Non-Final OA | Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
| 18285021 | ORAL GEL COMPOSITION AND USE THEREOF | Non-Final OA | DR. KURT WOLFF GMBH & CO. KG |
| 17996272 | TREATMENT OF HYPOTHALAMIC OBESITY | Final Rejection | Saniona A/S |
| 18130261 | METHODS AND COMPOSITIONS FOR REDUCING OXIDATIVE STRESS | Non-Final OA | Ojai Energetics PBC |
| 17427104 | IMMUNOMODULATOR | Non-Final OA | HITGEN INC. |
| 17319882 | Compositions And Methods For Reducing Food Cravings | Final Rejection | Nalpropion Pharmaceuticals LLC |
| 17911429 | OPHTHALMIC CHLOROPROCAINE GEL HAVING IMPROVED FUNCTIONALITY | Final Rejection | SINTETICA S.A. |
| 17632841 | CHOLECALCIFEROL FOR USE IN THE TREATMENT OF CELIAC DISEASE | Final Rejection | ABIOGEN PHARMA S.P.A. |
| 18189741 | PHARMACEUTICAL COMPOSITIONS USEFUL FOR THE TREATMENT OF TISSUE INJURY | Final Rejection | MedRegen, LLC |
| 18005976 | PDE3 inhibitors for treating viral infections | Non-Final OA | Breakthrough Medical Research B.V. |
| 17917175 | COMPOUNDS FOR THE PROPHYLAXIS AND/OR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME | Non-Final OA | SERVICIO ANDALUZ DE SALUD |
| 17786937 | USE OF ADEFOVIR DIPIVOXIL AND STRUCTURAL ANALOG THEREOF FOR TREATING PSEUDORABIES VIRUS | Final Rejection | YANG SHENG TANG COMPANY, LTD. |
| 17435592 | NEW AGENT FOR PROMOTING PHOSPHORYLATION OF eIF2a | Non-Final OA | ER Stress Research Institute, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy